Sign in

    Chong Hun • UBS

    Chong Hun's questions to Insmed Inc (INSM) leadership

    Chong Hun's questions to Insmed Inc (INSM) leadership • Q1 2025

    Question

    Chong Hun of UBS asked about the succession plan for the departed Chief Commercial Officer ahead of the Brensocatib launch and questioned the three-month timeline for cleaning the TPIP database.

    Answer

    CEO William Lewis stated the CCO search is underway with no rush, citing a strong existing commercial leadership structure and two years of launch preparation. He explained the TPIP timeline is not due to complexity but a commitment to making the database 'registrational quality' for future FDA submission, noting the timeline has actually been accelerated from prior guidance.

    Ask Fintool Equity Research AI

    Chong Hun's questions to Insmed Inc (INSM) leadership • Q1 2025

    Question

    An analyst from UBS asked about plans to name a permanent Chief Commercial Officer before the Brensocatib launch and whether the three-month timeline for TPIP data cleaning is unusual.

    Answer

    CEO William Lewis stated the company is not in a rush to fill the CCO role, citing the continued access to the departing executive and the presence of the COO, a former CCO. He emphasized that launch preparations began two years ago. Regarding TPIP, he explained the timeline is not due to any issues but reflects the process of ensuring the database is of 'registrational quality' for future FDA submission.

    Ask Fintool Equity Research AI